The large clinical pipeline under investigation worldwide highlights the continued advancement in CAR-T programs for both liquid cancers and solid tumors.
The importance of translating these successful trials to commercialization is clear. However, complexities in the manufacturing process challenge the industrialization of these therapies. In this webinar we examine how the application of one piece of process equipment across a range of unit operations can enable more robust, less complex, closed and automated CAR-T manufacturing.
Attendees will benefit from: